Chen Schor MBA, CPA
Chen Schor has served as a member of BrainStorm’s board of directors since 2011, and was appointed as a member of the Audit Committee in November 2017.
Mr. Schor is a global industry leader and has played a key role in building early-stage companies to regulatory approvals, IPOs, and M&A. He has vast experience in biotechnology, medical devices, business development, and private equity. Mr. Schor led multiple licensing and M&A transactions valued at over $8B with companies such as GlaxoSmithKline, Amgen, Pfizer, Bayer, Merck-Serono, and OncoGeneX Pharmaceuticals, and raised significant funds from reputable investors. Mr. Schor has a broad range of experience in multiple therapeutic areas including Neurology, Respiratory, Oncology, Auto-Immune, Genetic Diseases, and Women’s Health. Since December 2014, Mr. Schor has served as Executive Vice President and Chief Operating Officer of Synta Pharmaceuticals (SNTA). From March 2009 until September 2011, Mr. Schor served as Vice President of Business Development, global branded products at Teva Pharmaceuticals. Prior to joining Teva, Mr. Schor was Chief Business Officer at Epix Pharmaceuticals (formerly known as Predix Pharmaceuticals) from December 2003 until March 2009, leading the formation of more than $1.5B in collaborations with GlaxoSmithKline, Amgen, and additional pharmaceutical companies. Prior to joining Epix, Mr. Schor was a Partner at Yozma Venture Capital from September 1998 until December 2003, managing the fund’s investments in biotechnology and medical device companies.
Mr. Schor previously held positions at Arthur Anderson and BDO Consulting, an advisory firm. Mr. Schor holds an MBA, a BA in Biology, a BA in Economics, and is a Certified Public Accountant.